A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Authors
Psyrri, AEconomopoulou, P
Kotsantis, I
Koutsodontis, G
Cheila, M
Papaxoinis, Georgios
Pectasides, DG
Fountzilas, G
Krikoni, L
Souliotis, V
Affiliation
Internal Medicine/Medical Oncology, Attikon University Hospital, Athens, GreeceIssue Date
2018
Metadata
Show full item recordCitation
Psyrri A, Economopoulou P, Kotsantis I, Koutsodontis G, Cheila M, Papaxoinis G, et al. 1045O A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA). Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy287.001PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy287.001Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy287.001